[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100529810":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":92,"collaborators":19,"id":94,"slug":19,"hasResults":95,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":19,"eligibilityCriteria":99,"healthyVolunteers":95,"sex":100,"minAge":101,"maxAge":19,"enrollmentInfo":102,"targetDuration":19,"studyType":105,"phases":106,"briefSummary":108,"conditions":109,"keywords":19,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},{"fullName":5,"class":6},"Janssen Research & Development, LLC","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"JNJ-87890387","EXPERIMENTAL","In Part 1 (Dose escalation) participants will receive JNJ-87890387. The dose will be escalated sequentially until the recommended phase 2 dose (RP2D) regimen(s) have been identified. In Part 2 (Dose expansion), participants will receive JNJ-87890387 at the RP2D regimen(s) determined in Part 1.",[13],"Drug: JNJ-87890387",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","JNJ-87890387 will be administered.",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Janssen Research & Development, LLC Clinical Trial","STUDY_DIRECTOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Study Contact","CONTACT","844-434-4210","Participate-In-This-Study1@its.jnj.com",[31,44,54,64,73,83],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":19},"Start Midwest","RECRUITING","Grand Rapids","Michigan","49546","United States",{"type":39,"coordinates":40},"Point",[41,42],-85.66809,42.96336,{"lat":42,"lon":41},{"facility":45,"status":33,"city":46,"state":47,"zip":48,"country":37,"cosmosGeoPoint":49,"geoPoint":53,"contacts":19},"Sarah Cannon Research Institute","Nashville","Tennessee","37203",{"type":39,"coordinates":50},[51,52],-86.78444,36.16589,{"lat":52,"lon":51},{"facility":55,"status":33,"city":56,"state":19,"zip":57,"country":58,"cosmosGeoPoint":59,"geoPoint":63,"contacts":19},"Centre Leon Berard","Lyon","69008","France",{"type":39,"coordinates":60},[61,62],4.84789,45.74906,{"lat":62,"lon":61},{"facility":65,"status":33,"city":66,"state":19,"zip":67,"country":58,"cosmosGeoPoint":68,"geoPoint":72,"contacts":19},"Institut Gustave Roussy","Villejuif","94805",{"type":39,"coordinates":69},[70,71],2.35992,48.7939,{"lat":71,"lon":70},{"facility":74,"status":33,"city":75,"state":19,"zip":76,"country":77,"cosmosGeoPoint":78,"geoPoint":82,"contacts":19},"Hosp Univ Vall D Hebron","Barcelona","08035","Spain",{"type":39,"coordinates":79},[80,81],2.15899,41.38879,{"lat":81,"lon":80},{"facility":84,"status":33,"city":85,"state":19,"zip":86,"country":77,"cosmosGeoPoint":87,"geoPoint":91,"contacts":19},"Hosp. Univ. 12 de Octubre","Madrid","28041",{"type":39,"coordinates":88},[89,90],-3.70256,40.4165,{"lat":90,"lon":89},{"type":93,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100529810",false,"NCT06178614","A Study of JNJ-87890387 for Advanced Solid Tumors","A Phase 1 Study of JNJ-87890387, an Ectonucleotide Pyrophosphatase\u002FPhosphodiesterase Family Member 3 (ENPP3) x CD3 Bispecific Antibody, for Advanced Solid Tumors","Inclusion Criteria:\n\n* Have histologically or cytologically confirmed, metastatic, or unresectable solid tumor of one of the following types: a) Renal cell cancer (RCC)-clear cell or papillary carcinoma; b) Endometrioid ovarian cancer c) Endometrioid uterine carcinoma; d) Colorectal adenocarcinoma (CRC); e) Lung adenocarcinoma\n* Have measurable or evaluable disease: Part 1- Either measurable or evaluable disease; Part 2- At least 1 measurable lesion per RECIST v1.1. Participants with ovarian cancer without a measurable lesion must have disease evaluable per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) or have cancer antigen (CA) 125 greater than (\\>) 2\\*upper limit of normal (ULN) during screening\n* All participants in Part 1 and Part 2 must consent to provide an archived tumor tissue sample at screening\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at screening\n* Be willing and able to adhere to the lifestyle restrictions specified in this protocol.\n\nExclusion Criteria:\n\n* Active Central Nervous System (CNS) involvement with the exception of locally treated brain metastases that are clinically stable and asymptomatic for \\> 2 weeks and who are off or receiving low-dose corticosteroid treatment (less than or equal to \\[\\\u003C=\\]10 milligrams \\[mg\\] prednisone or equivalent) for at least 2 weeks prior to start of study treatment\n* Toxicity from prior anticancer therapy that has not resolved to Grade \\\u003C=1 (except alopecia, vitiligo, Grade \\\u003C=2 peripheral neuropathy, or endocrinopathies that are stable on hormone replacement)\n* History of Grade greater than or equal to (\\>=) 2 immune-related AE(s) with prior immunotherapy that led to discontinuation of previous immunotherapy with the exception of Grade 2 and Grade 3 immune-related AEs that responded to treatment and that did not recur following rechallenge. Endocrinopathies that are stable on hormone replacement therapy or that have resolved are allowed.\n* History of solid organ or hematologic stem cell transplantation\n* Any episode of partial or complete bowel obstruction requiring hospitalization within 30 days prior to first dose of study treatment","ALL","18 Years",{"count":103,"type":104},200,"ESTIMATED","INTERVENTIONAL",[107],"PHASE1","The purpose of this study is to determine safety and recommended phase 2 dose(s) (RP2Ds) of JNJ-87890387 and to determine the safety of JNJ-87890387 at the RP2D(s).",[110,111],"Neoplasms","Advanced Solid Tumors","2026-06-04",{"date":114,"type":115},"2026-06-05","ACTUAL",{"date":117,"type":115},"2023-12-14",{"date":119,"type":104},"2029-02-07",{"name":5,"class":6},6]